Vanguard Group Inc Biovie Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.4 - $0.56 $30,481 - $42,673	-76,203 Reduced 11.82%	568,372 $227,000
Q1 2024 May 10, 2024	BUY	$0.53 - $1.89 $155,144 - $553,250	292,725 Added 83.2%	644,575 $341,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $185,481 - $796,658	152,034 Added 76.09%	351,850 $443,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $5.17 $57,893 - $108,838	21,052 Added 11.78%	199,816 $681,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $104,217 - $211,237	25,481 Added 16.62%	178,764 $770,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $537,645 - $1.16 Million	109,948 Added 253.72%	153,283 $1.24 Million
Q4 2022 Feb 10, 2023	BUY	$3.86 - $42.0 $33,026 - $359,352	8,556 Added 24.6%	43,335 $336,000
Q3 2022 Nov 14, 2022	SELL	$1.38 - $25.6 $178,987 - $3.32 Million	-129,701 Reduced 78.86%	34,779 $86,000
Q3 2021 Nov 12, 2021	BUY	$6.69 - $16.93 $446,062 - $1.13 Million	66,676 Added 68.17%	164,480 $1.1 Million
Q2 2021 Aug 13, 2021	BUY	$10.57 - $21.61 $1.03 Million - $2.11 Million	97,804 New	97,804 $1.66 Million

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $64.3M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.